ISRACANN is targeting an undersupplied Israeli domestic market and anticipates near-term expansion to major European marketplaces

Focused on becoming the regions premier, low-cost cannabis producer, ISRACANN secured 3 farms in Israel with cultivation licenses totalling 580,000 sq. ft.


In 2007 Israel became the first country to allow medical research and cannabis cultivation. Positioned in the cannabis research capital of the world, we have relationships with the research, scientific and medical community to identify opportunities and develop a pipeline of products and devices.

Domestic Market

10,000 patients in Israel currently on waitlist with an estimated 50,000 anticipated by late 2019. Massively underserved domestic market presents significant and immediate opportunity

European Market

Pending Israel’s anticipated legislative framework for exports, Isracann intends to become a premier supplier of the European market (pop. over 740 million, double USA and Canada). EU medical market estimated to be $64B USD by 2028

Isracann Investor Relations


Stay up to date with IsraCann news & events